MBIO - Mustang Bio: Stock's Decline Opens Up Significant Potential For Late 2019
A Long Road Ahead
Mustang Bio (MBIO) has fallen over 70% the last 52 weeks as the company continues to struggle to push through their pipeline of immunotherapies. Progress will need to accelerate if the company wants to survive as MBIO has sky high product potential, but does not currently have even a phase III drug within their portfolio. Therefore, earnings continue to decline as they rapidly burn through cash (Figure 1). With no apparent catalysts scheduled through the first half of 2019, Mustang Bio looks like a strong avoid for